Macular Degeneration Drugs to Avoid

Several widely prescribed medications can harm the macula or complicate existing age-related macular degeneration (AMD), yet many people with AMD never learn which drugs deserve a closer look. The list spans multiple drug classes, from bladder medications and breast-cancer treatments to common blood thinners and even some eye supplements marketed for “macular health.” Knowing which drugs carry genuine risk lets you have a more informed conversation with every prescriber who manages your care.

Pentosan Polysulfate Sodium

Pentosan polysulfate sodium (sold as Elmiron) is prescribed for interstitial cystitis, a chronic bladder-pain condition. In 2018, researchers identified a distinctive pigmentary maculopathy in long-term users. The damage can closely mimic AMD itself, as well as inherited retinal conditions such as pattern dystrophy and Stargardt disease, making it easy to miss unless the prescribing history is reviewed carefully.¹ If you already have AMD and are also taking pentosan polysulfate, the overlap can obscure whether your vision loss is progressing from AMD, from the drug, or both. The risk rises with cumulative exposure, so anyone who has been on the drug for years should bring it up with their retina specialist.

Tamoxifen

Tamoxifen is a mainstay of breast cancer treatment and prevention, but long-term use can deposit tiny crystalline structures in the macula. These refractile deposits sit within the retinal layers, and over time the drug can also cause fluid to accumulate in the macula, reducing sharpness of central vision.² One study found that tamoxifen-treated patients were roughly three and a half times more likely to develop intraretinal crystals than untreated patients.³

The tricky part is that some of this damage may not fully reverse after the drug is stopped, because the crystalline deposits may represent a form of permanent nerve-fiber injury.⁴ That does not mean you should abruptly stop tamoxifen if you have AMD; the drug may be keeping a cancer in check. But anyone on long-term tamoxifen should get regular dilated eye exams with imaging so that early signs of macular toxicity can be weighed against the cancer-prevention benefit.⁵

MEK Inhibitors Used in Cancer Therapy

MEK inhibitors (drugs like trametinib, cobimetinib, and selumetinib) are targeted cancer therapies used for melanoma and other malignancies. They have a well-documented tendency to cause fluid to collect under the retina, producing something that looks a lot like central serous chorioretinopathy. The fluid buildup is usually self-limiting, but it can temporarily blur vision and is concerning in someone whose macula is already compromised by AMD.⁶ Unlike the fluid that AMD itself produces through leaky new blood vessels, MEK-inhibitor fluid does not show dye leakage on a fluorescein angiogram, which helps distinguish the two conditions.⁷

If you are being treated with a MEK inhibitor and also have AMD, your oncologist and your eye doctor both need to be aware of the overlap. Dose adjustments or treatment pauses sometimes resolve the retinal fluid, but stopping a cancer drug carries its own serious risks, so these decisions are never straightforward.⁸

Thioridazine and Older Antipsychotics

Thioridazine, an older antipsychotic rarely prescribed today, is one of the clearest examples of drug-induced retinal toxicity. In the first year after exposure, the retina develops a granular pigment pattern that can evolve into patchy areas of damage. Visual function and electrical responses of the retina often improve initially after the drug is stopped, but some patients go on to develop areas of tissue thinning and vision loss years later, likely because retinal cells injured during drug exposure eventually die off.⁹ While thioridazine has largely been replaced by newer medications, people who took it in past decades may still carry subclinical retinal damage that could be confused with early AMD.

Blood Thinners and Antiplatelet Drugs

If you have the “wet” form of AMD, where abnormal blood vessels leak beneath the retina, blood thinners deserve extra attention. Patients on anticoagulant or antiplatelet therapy who develop subretinal hemorrhages tend to have significantly larger bleeds. One study found the average hemorrhage in patients on blood thinners covered about ten disc areas, compared with roughly three disc areas in patients not taking them.¹⁰ A separate study focusing specifically on warfarin found that a patient with AMD and a massive intraocular hemorrhage was nearly twelve times more likely to be on anticoagulant therapy than a patient without such a bleed.¹¹

This absolutely does not mean you should stop taking a blood thinner on your own. If you are on warfarin or another anticoagulant for atrial fibrillation, a mechanical heart valve, or a history of blood clots, the cardiovascular benefit generally outweighs the eye risk. But your retina specialist should know about every anticoagulant and antiplatelet drug you take, because it can change the urgency of monitoring and influence how aggressively hemorrhagic complications are managed.

Corticosteroids

Systemic corticosteroids, whether taken orally or given intravenously, are a well-known trigger for central serous chorioretinopathy (CSC), a condition in which fluid pools under the retina. Chronic CSC can look remarkably similar to wet AMD, and when doctors mistake one for the other, continuing steroids makes the problem worse rather than better.¹² Even nasal sprays and inhaled steroids for asthma have been linked to CSC in susceptible people, though the risk is much lower than with oral prednisone. If you have AMD and are prescribed a course of steroids for another condition, mention your eye diagnosis so your doctor can weigh alternatives or shorten the course where possible.

Fingolimod for Multiple Sclerosis

Fingolimod (Gilenya), an oral drug used for relapsing multiple sclerosis, increases the risk of macular edema, particularly in people whose retinas are already vulnerable. The risk goes up in patients who have diabetes, a history of eye inflammation, or who have recently had cataract surgery.¹³ For someone who also has AMD, fingolimod-related macular swelling can be an unwelcome second insult to an already compromised retina. Current guidelines call for an eye exam before starting fingolimod and again a few months into treatment. If you have AMD or diabetic eye disease, that monitoring schedule becomes especially important.

PDE5 Inhibitors and Choroidal Blood Flow

Sildenafil (Viagra), tadalafil (Cialis), and related drugs work by relaxing blood vessels, and the choroid, the blood-vessel-rich layer that sits directly behind the retina, responds to them as well. After a dose of sildenafil, choroidal thickness increases by roughly six to nine percent within a few hours.¹⁴ A thicker, more engorged choroid may, in theory, increase fluid leakage or stress an already fragile retinal-pigment-epithelium layer in someone with AMD.¹⁵

The evidence here is more cautionary than definitive. One study found that the choroid’s ability to respond to sildenafil decreased with age but was not significantly affected by the presence of AMD itself, suggesting the choroidal vasculature in AMD eyes is not dramatically different in its compliance.¹⁶ Occasional use for erectile dysfunction is unlikely to be the thing that tips someone from stable dry AMD into wet AMD, but chronic daily use in a person with advanced disease warrants a conversation with a retina specialist.

Latanoprost and Other Prostaglandin Eye Drops

Latanoprost (Xalatan) and other prostaglandin-analog eye drops are first-line treatments for glaucoma, and many people use them alongside AMD management. In susceptible eyes, these drops can cause cystoid macular edema, a swelling pattern in which tiny fluid-filled pockets form in the central retina. The risk is highest in eyes that already have a weakened blood-retinal barrier from conditions like diabetes, prior uveitis, complicated cataract surgery, or epiretinal membrane.¹⁷ In the reported cases, macular edema resolved after latanoprost was stopped, sometimes with the help of anti-inflammatory drops. If you have both glaucoma and AMD, your eye doctor can choose a pressure-lowering drop less likely to provoke macular swelling.

Beta-Carotene Supplements

This one catches people off guard because beta-carotene was part of the original AREDS supplement formula widely recommended for AMD. In the large AREDS2 trial, participants randomly assigned to receive beta-carotene were about twice as likely to develop lung cancer at the ten-year mark compared with those who received lutein and zeaxanthin instead.¹⁸ The lung-cancer risk was concentrated in current and former smokers.¹⁹ As a result, the updated AREDS2 formula replaced beta-carotene with lutein and zeaxanthin. If you are still taking an older-formula eye vitamin that lists beta-carotene on the label, switching to a current AREDS2-based product eliminates that cancer risk while delivering at least comparable eye benefits.

Vitamin A Supplements and Stargardt-Like Disease

Some forms of macular disease that look like AMD turn out to be late-onset Stargardt disease, a genetic condition caused by mutations in the ABCA4 gene. In animal models, high-dose vitamin A accelerated the buildup of toxic waste products in the retinal pigment epithelium, prompting some clinicians to advise Stargardt patients to avoid vitamin A supplements.²⁰ A systematic review found the human evidence for this harm was sparse, but the precautionary advice persists because there is also no evidence ruling out the risk. The practical concern for AMD patients is that if what was diagnosed as AMD is actually late-onset Stargardt disease, taking a standard AREDS2 supplement containing vitamin A (as zinc and copper combinations sometimes accompany A-containing multivitamins) could theoretically speed the damage. Genetic testing can resolve this ambiguity when the clinical picture is unclear.

The Anti-VEGF Paradox

Anti-VEGF injections (ranibizumab, bevacizumab, aflibercept) are the gold-standard treatment for wet AMD and have saved millions of people from severe vision loss. Yet a growing body of evidence suggests these same injections are associated with the development or progression of geographic atrophy (GA), the advanced dry form of AMD. A systematic review and meta-analysis found that both the total number of injections and the frequency of dosing were linked to greater GA incidence and progression.²¹ Data from the CATT trial showed that monthly injections led to more GA progression than as-needed dosing, and that ranibizumab appeared to carry a somewhat higher GA risk than bevacizumab.²²

This does not mean you should refuse anti-VEGF treatment. Untreated wet AMD typically leads to rapid, severe central vision loss, and the benefit of controlling leaky blood vessels far outweighs the incremental GA risk in most patients. What the evidence does suggest is that treat-and-extend or as-needed dosing schedules, which use fewer total injections, may be preferable to rigid monthly injection protocols when clinically appropriate. Discuss the schedule with your retina specialist, especially if you already show signs of dry AMD in addition to the wet component.

Separately, some observers have worried about systemic cardiovascular risk from anti-VEGF injections, since VEGF plays a role in blood-vessel health throughout the body. A pooled analysis of randomized trials found no statistically significant increase in major cardiovascular events with anti-VEGF treatment compared with controls.²³ However, the concern has not been fully laid to rest, and clinicians tend to exercise extra caution in patients who have recently had a stroke or heart attack.²⁴

Drugs That May Actually Help

Population-level studies have identified a handful of medications originally developed for other conditions that appear to be associated with a lower risk of AMD development or slower progression. Metformin (widely used for type 2 diabetes) and statins (used for high cholesterol) are the most studied, with several large database analyses suggesting a modest protective association.²⁵ More recently, data-mining studies have pointed to fluoxetine (Prozac) and levodopa as potential candidates for AMD risk reduction, though these findings are still in the observational stage and not ready for clinical recommendations. No one should start taking metformin or a statin purely for AMD protection at this point, but if you already take one of these drugs for its intended purpose, the early signals are encouraging rather than alarming.

How to Manage the Full Picture

The common thread running through all of these drug interactions is that AMD rarely exists in isolation. Most people diagnosed with it are older adults juggling multiple prescriptions from multiple doctors. A cardiologist prescribing warfarin may have no idea that their patient also has wet AMD and is at higher risk for a catastrophic subretinal bleed. A urologist renewing pentosan polysulfate may not realize that the patient’s worsening vision is partly drug-related rather than purely age-related. Keeping a single updated medication list and sharing it with every specialist, including your retina doctor, is the most practical step you can take.

When reviewing supplements, check labels carefully. Many “eye health” formulas still use beta-carotene, and some multivitamins marketed to older adults contain high-dose vitamin A that may not be appropriate if there is any question about the exact genetic diagnosis behind your macular disease. If your condition has atypical features or does not respond as expected to standard AMD treatment, ask whether genetic testing might be worthwhile to rule out conditions like late-onset Stargardt disease that masquerade as AMD but call for different supplement advice.